> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Anika Therapeutics Reassesses Hyalafast Approval Path After FDA Rejects Submitted Clinical Data
- URL: https://www.bullished.co/anika-therapeutics-reassesses-hyalafast-approval-path-after-fda-rejects-submitted-clinical-10883d5a/
- Published: 2026-11-06T14:31:27.000Z
- Updated: 2026-11-06T14:31:27.000Z
- Description: Management cuts its commercial growth outlook but raises the floor for total revenue growth as its partner channel contributes more.
- Author: Matteo Parrino
- Tags: Earnings, ANIK, Industry: Healthcare

[Anika Therapeutics](https://www.bullished.co/tag/anik/), which makes hyaluronic-acid-based medical products mainly for orthopedic care, is reassessing its route to U.S. approval for Hyalafast after the FDA deemed its application not approvable in October, primarily because of the submitted clinical data. President and Chief Executive Officer Steve Griffin described the setback on the company’s earnings call Friday, alongside a cut to its commercial growth forecast.

## Hyalafast Stays Outside The Forecast

Griffin said management still believes in Hyalafast’s U.S. potential and is weighing regulatory options, including talks with the FDA about “the additional clinical evidence that may be required to support a future approval.”

The U.S. regulatory outcome is separate from Anika’s current revenue forecast. Management removed assumed U.S. Hyalafast sales last quarter and now counts only products approved or cleared in the markets where they would be sold.

Anika’s portfolio spans office-based osteoarthritis injections—Orthovisc, Monovisc and Cingal—and surgical regenerative products, including Hyalofast, Tactoset and the Integrity tendon-repair scaffold. Johnson & Johnson MedTech markets Orthovisc and Monovisc in the United States; Anika uses distributors internationally and manufactures its hyaluronic-acid-based products in Bedford, Massachusetts.

Cingal’s U.S. development work continues separately. Study enrollment finished in September, ahead of the previous year-end target, and management expects the bioequivalence study report in the first quarter of 2027\. Manufacturing-control work is also needed to support an FDA drug approval application, which Griffin expects to submit before year-end 2027.

## Integrity Softness Cuts Commercial Expectations

Anika now expects 2026 commercial revenue growth of 9%–13%, down from 12%–18%. Griffin attributed the reduction to lighter-than-expected Integrity sales and said fourth-quarter growth would not recover all the summer softness in U.S. elective surgery.

Integrity nevertheless grew more than 30% year over year in the third quarter and 37% through the first nine months. Its trailing-12-month revenue reached $7.5 million. Larger implant sizes introduced in late 2025 and early 2026 expanded use into foot, ankle and knee procedures, while new instrumentation launched in September gives surgeons another deployment option.

The commercial channel posted record third-quarter revenue of $14 million, up 17%. International osteoarthritis pain-management revenue grew 19%, and regenerative-solutions revenue increased 12%.

A stronger partner channel offset the lower commercial expectations. Ian McLeod, Anika’s Senior Vice President, Chief Accounting Officer, and Treasurer, raised expected OEM revenue growth to 5%–9% from 0%–5%. That channel supplies products through partners and generated $16.6 million in quarterly revenue, up 5%.

Companywide revenue-growth guidance is now 6%–10%, versus 5%–10% previously. For 2027, management reaffirmed flat-to-5% total growth and expects OEM revenue to be flat to modestly lower, with U.S. osteoarthritis pricing declines included in the outlook. McLeod corrected his initial commercial forecast during questions: the preliminary 2027 range is 5%–15%.

## Margins Improve, Manufacturing Takes Priority

Total third-quarter revenue reached [$30.6 million](https://wtop.com/national/2026/11/anika-q3-earnings-snapshot/?ref=bullished.co), up 10% from $27.8 million. Gross margin improved to 62% from 56% a year earlier but fell from the second quarter’s 65%, primarily because of product mix, including the reintroduced wound product Hyla Matrix.

The operating loss narrowed to $0.7 million from $3.2 million. Adjusted earnings before interest, taxes, depreciation and amortization reached $5.1 million, versus $0.9 million a year earlier and $7.1 million in the second quarter. Management raised its full-year adjusted margin forecast to 15%–17% from 13%–17%.

Anika generated $8.4 million in quarterly operating cash and spent $1.7 million on capital investments. September cash totaled $45 million, compared with $38.4 million at June’s end. Griffin put manufacturing expansion first in the company’s capital priorities, followed by investment in its U.S. sales force.

A new 10-year distribution agreement with existing veterinary partner Boehringer Ingelheim improves transfer pricing, royalties and minimum purchases. Anika expects $8 million in payments: $4 million upfront in the first quarter of 2027 and $4 million tied to commercial volumes. Griffin said the upfront payment would help fund capital spending.

Griffin expects positive operating cash flow in the fourth quarter while Anika continues investing in manufacturing capacity.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Anika: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/anika-q3-earnings-snapshot-122239796.html?ref=bullished.co) — Associated Press
- [Anika: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/11/anika-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [Anika: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/anika-q3-earnings-snapshot/616-6ba86721-3eb1-47b4-b489-d9fddbc12f3a?ref=bullished.co) — Associated Press
- [Anika: Q3 Earnings Snapshot | wfaa.com](https://www.wfaa.com/article/syndication/associatedpress/anika-q3-earnings-snapshot/616-6ba86721-3eb1-47b4-b489-d9fddbc12f3a?ref=bullished.co) — Associated Press
- [Anika: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/anika-q3-earnings-snapshot/616-6ba86721-3eb1-47b4-b489-d9fddbc12f3a?ref=bullished.co) — Associated Press

### More on Anika Therapeutics

- [Anika Lifts 2026 Profit Outlook And Signs 10-Year Hyvisc Deal, But FDA Rejects Hyalofast](https://www.bullished.co/anika-lifts-2026-profit-outlook-and-signs-10-year-hyvisc-deal-but-fda-rejects-hyalofast-014e9827/)

[All Anika Therapeutics (ANIK) coverage →](https://www.bullished.co/tag/anik/)